Royalty Pharma plc Class A Ordinary Shares (RPRX)

FairStock Score: 43/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett-and-Graham-style investor, I see Royalty Pharma as an unusual business: it buys biopharmaceutical royalties, with royalties on about 35 marketed therapies and 20 development-stage candidates, and it does so with only 100 employees. That can be a durable, cash-generative model, and trailing free cash flow of $3.0B, an 8.3% FCF yield at the 2026-10-26 close, and a low beta of 0.43 are real attractions. Revenue is also growing: fiscal Q2 2026, the quarter ended 2026-06-30, had revenue of $674.1M versus $578.7M in fiscal Q2 2025. But the quality is uneven. In fiscal Q2 2026 net income was only $17.9M, or $0.04 per diluted share, a 2.65% margin, and filed annual net income fell from $1.1B in FY2023 to $859.0M in FY2024 and $770.9M in FY2025. FairStock classifies it as a SLOW GROWER — Shrinking, with profit down about 4.6% a year over five years and revenue up only 2.3%; the provided profit growth metric is -44.42% against revenue growth of 16.50%. ROCE of 5.09% is modest, D/E is 0.92, Piotroski is 5/9, and Altman Z is 2.43. The royalty portfolio may provide some staying power, but low returns and falling profits argue against calling it a wide moat. Valuation is the sticking point: FairStock's P/E is 34.82, P/B 4.22, EV/EBITDA 25.48, and the Graham Number is $25.33 against a $64.76 close, a margin of safety of -152.11%. The cash flow is appealing, but the price already assumes a lot.

In plain English: Royalty Pharma buys rights to biopharmaceutical royalties, so it collects payments when drugs sell. Revenue is growing and cash flow is strong, but profits have fallen recently and the latest quarter had a very thin profit margin. At the 2026-10-26 close of $64.76, the shares look expensive compared with reported profits and net worth, even though the business has some defensive qualities.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer